Remote personalised exercise in axial spondyloarthritis: the SPARK trial – protocol for a 6-month randomised controlled trial

Read full text Summarise with VIRAT
Authors: Birgitte Nellemann, Camilla Fongen, Hanne Solveig Dagfinrud, Inger Jorid Berg, Eirik Klami Kristianslund, Joe Sexton, Kristine Røren Nordén, Siri Lillegraven, Nina Østerås, TS Jørgensen, Loreto Carmona, Silje Halvorsen Sveaas
+1 more Sella Aarrestad Provan
Cited by: 0
References: 51

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Current international guidelines recommend exercise as a first-line treatment of axial spondyloarthritis (SpA). However, there is no consensus on the mode and volume required to effectively reduce disease activity. It is advised that exercise for patients with SpA align with recommendations for the general population. For exercise to be sustainable and beneficial, it must be integrated into daily life and strategies to ensure long-term commitment are essential. The SpA Kardio (SPARK) trial aims to assess the impact of a remote, individually tailored exercise programme in patients with SpA with the proportion of patients reaching Axial Spondyloarthritis Disease Activity Score (ASDAS) inactive at 3 months as the primary outcome. The exercise includes high-intensity cardiorespiratory intervals and muscle strength exercises, with digital follow-up and monitoring, in patients with SpA. The SPARK programme includes regular supervision, personalised follow-up, goal-setting and education delivered through an application available on smartphones or tablets. METHODS AND ANALYSIS: The SPARK trial is a randomised controlled superiority trial. Individuals recently diagnosed with SpA by a rheumatologist with disease activity measured by the ASDAS ≥1.3 who have not used biological disease-modifying antirheumatic drugs (bDMARDs) are eligible for inclusion. Consenting individuals will be randomised to treatment as usual (n=130) or the SPARK programme (n=130) with 12-week duration. After 12 weeks, all participants will be rerandomised to either a supervised or an unsupervised SPARK programme for weeks 12-24. The primary outcome will be achievement of an inactive disease state (ASDAS

Fields of Study & Subjects

Spondyloarthritis Studies and Treatments Musculoskeletal pain and rehabilitation Physical Activity and Health

Publication details

Journal / source
BMJ Open
Volume
16
Issue
3
Pages
e112420–e112420
Publication date
1 March 2026
Language
EN